Albert F. LoBuglio

12.0k total citations · 1 hit paper
189 papers, 9.5k citations indexed

About

Albert F. LoBuglio is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology and Molecular Biology. According to data from OpenAlex, Albert F. LoBuglio has authored 189 papers receiving a total of 9.5k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Radiology, Nuclear Medicine and Imaging, 58 papers in Immunology and 52 papers in Molecular Biology. Recurrent topics in Albert F. LoBuglio's work include Monoclonal and Polyclonal Antibodies Research (52 papers), Radiopharmaceutical Chemistry and Applications (36 papers) and Immunotherapy and Immune Responses (27 papers). Albert F. LoBuglio is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (52 papers), Radiopharmaceutical Chemistry and Applications (36 papers) and Immunotherapy and Immune Responses (27 papers). Albert F. LoBuglio collaborates with scholars based in United States, Canada and France. Albert F. LoBuglio's co-authors include M.B. Khazaeli, Robert M. Conry, James H. Jandl, Mansoor N. Saleh, Ruby F. Meredith, Paul A. Chervenick, Richard Wheeler, William E. Grizzle, Donald J. Buchsbaum and Arthur L. Sagone and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Albert F. LoBuglio

187 papers receiving 8.9k citations

Hit Papers

Red Cells Coated with Immunoglobulin G: Binding and Spher... 1967 2026 1986 2006 1967 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Red Cells Coated with Immunoglobulin G: Binding and Sphering by Mononuclear Cells in Man
    1967 399 citations Albert F. LoBuglio et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Albert F. LoBuglio United States 54 3.6k 3.0k 2.9k 2.6k 1.1k 189 9.5k
Ivan D. Horak United States 62 4.8k 1.3× 5.7k 1.9× 3.9k 1.4× 1.8k 0.7× 880 0.8× 205 14.0k
Gert Riethmüller Germany 47 3.1k 0.9× 3.3k 1.1× 5.1k 1.8× 1.9k 0.7× 1.1k 1.0× 112 10.4k
Pier Giorgio Natali Italy 61 5.3k 1.5× 2.6k 0.9× 3.1k 1.1× 1.7k 0.7× 984 0.9× 260 11.3k
Zenon Steplewski United States 51 6.2k 1.7× 3.4k 1.1× 3.1k 1.1× 5.3k 2.0× 822 0.8× 172 11.0k
Peter A. Kiener United States 59 3.8k 1.1× 4.4k 1.5× 1.6k 0.6× 1.7k 0.6× 1.2k 1.1× 124 10.6k
Roy R. Lobb United States 56 5.3k 1.5× 4.8k 1.6× 1.5k 0.5× 2.0k 0.8× 742 0.7× 134 14.3k
Tatsuro Irimura Japan 58 7.0k 1.9× 4.0k 1.3× 1.9k 0.7× 1.3k 0.5× 607 0.6× 286 11.7k
Walther J. van Venrooij Netherlands 60 6.0k 1.7× 3.4k 1.1× 1.2k 0.4× 5.1k 1.9× 564 0.5× 189 16.2k
Jeffrey A. Ledbetter United States 52 3.8k 1.1× 10.4k 3.5× 2.6k 0.9× 2.7k 1.0× 402 0.4× 118 14.8k
Karl Erik Hellström United States 51 3.1k 0.9× 6.5k 2.2× 3.8k 1.3× 2.2k 0.8× 1.2k 1.1× 172 11.8k

Countries citing papers authored by Albert F. LoBuglio

Since Specialization
Citations

This map shows the geographic impact of Albert F. LoBuglio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Albert F. LoBuglio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Albert F. LoBuglio more than expected).

Fields of papers citing papers by Albert F. LoBuglio

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Albert F. LoBuglio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Albert F. LoBuglio. The network helps show where Albert F. LoBuglio may publish in the future.

Co-authorship network of co-authors of Albert F. LoBuglio

This figure shows the co-authorship network connecting the top 25 collaborators of Albert F. LoBuglio. A scholar is included among the top collaborators of Albert F. LoBuglio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Albert F. LoBuglio. Albert F. LoBuglio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Forero, Andres, Yufeng Li, Dongquan Chen, et al.. (2016). Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes. Cancer Immunology Research. 4(5). 390–399. 124 indexed citations
2.
Londoño-Joshi, Angelina I., Rebecca C. Arend, Wenyan Lü, et al.. (2014). Effect of Niclosamide on Basal-like Breast Cancers. Molecular Cancer Therapeutics. 13(4). 800–811. 72 indexed citations
3.
Vaklavas, Christos, Ruby F. Meredith, Sui Shen, et al.. (2013). Phase I Study of a Modified Regimen of 90 Yttrium–Ibritumomab Tiuxetan for Relapsed or Refractory Follicular or Transformed CD20+ Non-Hodgkin Lymphoma. Cancer Biotherapy and Radiopharmaceuticals. 28(5). 370–379. 3 indexed citations
4.
Meredith, Ruby F., Zhiying You, Ronald D. Alvarez, et al.. (2012). Predictors of Long-Term Outcome from Intraperitoneal Radioimmunotherapy for Ovarian Cancer. Cancer Biotherapy and Radiopharmaceuticals. 27(1). 36–40. 11 indexed citations
5.
Shen, Sui, Andres Forero, Ruby F. Meredith, & Albert F. LoBuglio. (2011). Biodistribution and Dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in Patients with Metastatic Colorectal Adenocarcinoma. Cancer Biotherapy and Radiopharmaceuticals. 26(1). 127–133. 10 indexed citations
6.
Forero‐Torres, Andres, Mansoor N. Saleh, J. Galleshaw, et al.. (2010). Pilot Trial of Preoperative (Neoadjuvant) Letrozole in Combination With Bevacizumab in Postmenopausal Women With Newly Diagnosed Estrogen Receptor— or Progesterone Receptor—Positive Breast Cancer. Clinical Breast Cancer. 10(4). 275–280. 29 indexed citations
7.
Oliver, Patsy G., Albert F. LoBuglio, Kurt R. Zinn, et al.. (2008). Treatment of Human Colon Cancer Xenografts with TRA-8 Anti-death Receptor 5 Antibody Alone or in Combination with CPT-11. Clinical Cancer Research. 14(7). 2180–2189. 30 indexed citations
8.
Vickers, Selwyn M., Kurt R. Zinn, Zhi Huang, et al.. (2007). TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth. Molecular Cancer Therapeutics. 6(12). 3198–3207. 39 indexed citations
9.
Triozzi, Pierre L., Jatin J. Shah, Wayne Aldrich, et al.. (2006). Anti-GD3 Monoclonal Antibody Effects on Lymphocytes and Antibody-Dependent Cellular Cytotoxicity. Cancer Biotherapy and Radiopharmaceuticals. 21(6). 553–560. 5 indexed citations
10.
Shen, Sui, Ruby F. Meredith, Jun Duan, et al.. (2005). Testicular Uptake and Radiation Dose in Patients Receiving Zevalin ™ and Pretarget ™ CC49Fusion Protein. Cancer Biotherapy and Radiopharmaceuticals. 20(1). 110–118. 3 indexed citations
11.
Forero‐Torres, Andres, Sui Shen, Hazel B. Breitz, et al.. (2005). Pretargeted Radioimmunotherapy (RIT) with a Novel Anti-TAG-72 Fusion Protein. Cancer Biotherapy and Radiopharmaceuticals. 20(4). 379–390. 20 indexed citations
12.
Rogers, Buck E., Peter L. Roberson, Sui Shen, et al.. (2005). Intraperitoneal Radioimmunotherapy with a Humanized Anti-TAG-72 (CC49) Antibody with a Deleted CH2 Region. Cancer Biotherapy and Radiopharmaceuticals. 20(5). 502–513. 19 indexed citations
13.
Forero, Andres, Ruby F. Meredith, M.B. Khazaeli, et al.. (2005). Phase I Study of 90 Y-CC49 Monoclonal Antibody Therapy in Patients with Advanced Non-Small Cell Lung Cancer: Effect of Chelating Agents and Paclitaxel Co-Administration. Cancer Biotherapy and Radiopharmaceuticals. 20(5). 467–478. 19 indexed citations
14.
Forero, Andres, Ruby F. Meredith, M.B. Khazaeli, et al.. (2003). A Novel Monoclonal Antibody Design for Radioimmunotherapy. Cancer Biotherapy and Radiopharmaceuticals. 18(5). 751–759. 22 indexed citations
15.
Meredith, Ruby F., Sui Shen, Daniel J. Macey, et al.. (2003). Comparison of Biodistribution, Dosimetry, and Outcome from Clinical Trials of Radionuclide-CC49 Antibody Therapy. Cancer Biotherapy and Radiopharmaceuticals. 18(3). 393–404. 13 indexed citations
16.
Robert, Francisco, et al.. (2003). Chemotherapy Tolerance After Radioimmunotherapy with 90 Y-CC49 Monoclonal Antibody in Patients with Advanced Non-Small Cell Lung Cancer: Clinical Effects and Hematologic Toxicity. Cancer Biotherapy and Radiopharmaceuticals. 18(3). 317–325. 7 indexed citations
17.
Shen, Sui, et al.. (2003). Comparison of Methods for Predicting Myelotoxicity for Non-Marrow Targeting I-131-Antibody Therapy. Cancer Biotherapy and Radiopharmaceuticals. 18(2). 209–215. 6 indexed citations
18.
Chaudhuri, Tandra R., Zhihong Cao, Cristina Rodríguez-Burford, Albert F. LoBuglio, & Kurt R. Zinn. (2002). A Non-Invasive Approach for Monitoring Breast Tumor Cells During Therapeutic Intervention. Cancer Biotherapy and Radiopharmaceuticals. 17(2). 205–212. 5 indexed citations
19.
Meredith, Ruby F., Ronald D. Alvarez, Edward E. Partridge, et al.. (2001). Intraperitoneal Radioimmunochemotherapy of Ovarian Cancer: A Phase I Study. Cancer Biotherapy and Radiopharmaceuticals. 16(4). 305–315. 70 indexed citations
20.
Kataria, Yash P., Albert F. LoBuglio, & Philip A. Bromberg. (1976). Sarcoid lymphocytes: spontaneous transformation and release of macrophage migration inhibition activity.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 113(3). 315–23. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ivan D. Horak Breakdown of academic impact, for papers by Gert Riethmüller Breakdown of academic impact, for papers by Pier Giorgio Natali Breakdown of academic impact, for papers by Zenon Steplewski Breakdown of academic impact, for papers by Peter A. Kiener Breakdown of academic impact, for papers by Roy R. Lobb Breakdown of academic impact, for papers by Tatsuro Irimura Breakdown of academic impact, for papers by Walther J. van Venrooij Breakdown of academic impact, for papers by Jeffrey A. Ledbetter Breakdown of academic impact, for papers by Karl Erik Hellström
Rankless by CCL
2026